Business Wire

AL-ADTRAN

13.6.2024 14:01:33 CEST | Business Wire | Press release

Share
Adtran sets new industry benchmarks with optical pumping cesium atomic clocks

Adtran today launched two new optical cesium atomic clocks that set new standards in network time synchronization: the OSA 3300 Super High-Performance (OSA 3300 SHP) and the OSA 3350 Super Enhanced Primary Reference Clock+ (OSA 3350 SePRC+). As part of Adtran’s Oscilloquartz portfolio of industry-first optical cesium clocks, the devices leverage unique, state-of-the-art optical pumping technology to meet evolving demands across applications from scientific research to critical PNT infrastructure. The OSA 3300 SHP offers exceptional stability and accuracy, making it a valuable tool for metrology institutes and scientific research facilities. In contrast, the OSA 3350 SePRC+ is specifically designed to enhance holdover capabilities for PNT services. It maintains 100 days of 100-nanosecond precision, providing continuous and accurate timing even in environments where GPS/GNSS is unavailable. This makes it a crucial component for ensuring the integrity of mission-critical networks and supporting vital infrastructure and defense operations with reliable backup timing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613778509/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s new optical pumping cesium clocks are a significant breakthrough for the networking industry. (Photo: Business Wire)

“Our two new optical cesium clocks represent a major breakthrough, offering substantial benefits to a wide variety of industries. Take the OSA 3350 SePRC+, for instance – it ensures 100-nanosecond accuracy over a span of more than three months. This level of precision and stability is critical for infrastructures relying on continuous PNT services, providing our customers with supreme reliability and robust protection against escalating cyber threats to GPS/GNSS,” said Gil Biran, GM of Oscilloquartz, Adtran. “In an era marked by rising global tensions and heightened risks of state-sponsored interference in satellite communications, our latest innovation has arrived at a pivotal moment. It will greatly enhance our capacity to address the demand for secure and reliable network timing around the world. Building on our 75-year legacy and unmatched expertise, the OSA 3350 SePRC+ exemplifies our commitment to excellence in assured PNT technology. As pioneers in the field, we continue to set new benchmarks, consistently improving standards to meet the dynamic needs of our customers and the broader market.”

The OSA 3300 SHP and OSA 3350 SePRC+ redefine the capabilities of PRCs and ePRCs, unlocking new possibilities in their respective domains. The OSA 3300 SHP, with its superior Allan Deviation (ADEV) performance – twice as accurate as the 3300 HP with the same 10-year lifespan – ensures exceptional stability and accuracy, making it an ideal choice for metrology institutes and scientific research facilities. Its advanced feature set enables these institutions to achieve new levels of precision in their timekeeping and calibration processes, directly driving advancements in scientific research and industrial applications. Meanwhile, the OSA 3350 SePRC+ is specifically designed to enhance holdover capabilities for PNT services. This high-end optical cesium clock, together with our Super ePRTC+ combiner can maintain 100 days of 100-nanosecond precision, far exceeding previous industry records, and ensuring continuous and accurate timing even in environments where GPS/GNSS are unavailable.

“Our OSA 3300 SHP provides unprecedented accuracy in timekeeping, maintaining nanosecond precision over extended periods. This level of enhanced accuracy and stability is crucial for scientific research and metrology, supporting high-precision experiments and the calibration of instruments to the highest standards. The 3300 SHP allows researchers to conduct groundbreaking experiments in fields like quantum mechanics and relativity, where extreme accuracy is paramount,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, Adtran. “At Oscilloquartz, we’re dedicated to advancing time and frequency technology, leveraging our world-renowned Swiss expertise in this field. Our latest innovations demonstrate our commitment to delivering superior solutions that meet the evolving demands of our customers, driving progress in both scientific research and industrial applications.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613778509/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye